Lung Cancer Update, Issue 3, 2016 (Video Program) - Video 8Clinical trials of osimertinib as first-line therapy for EGFR mutation-positive metastatic NSCLC
1:21 minutes.
TRANSCRIPTION:
DR MOK: Osimertinib as a first line is being studied in the FLAURA study. And then that study is actually ongoing quite well, and the accrual is coming on very fast. DR LOVE: Any sense about whether you think osimertinib would be more effective? And also in terms of brain mets? DR MOK: Right. So there are 2 sets of data. One set of data is on the 60 patients who received osimertinib as a first line, was reported by Ramalingam in Geneva, ELCC. And reported a median progression-free survival, 19.6 months, which is quite impressive. And then the other set of data about the brain is that would be reported by James Yang in ASCO, and it’s not so-called a big series, but then there will be the cases, particularly looking at the CNS response. And there will be including some of the pharmacokinetic data and even CSF data. DR LOVE: I mean, gefitinib/erlotinib can cause responses in the brain. Do you think, when we look at these data, we’re going to look at this and go, indirectly, and think that maybe this is going to be more effective in the brain, osimertinib? DR MOK: So there’s already some known difference between gefitinib and erlotinib in terms of CNS penetration. There are better pharmacokinetic data from erlotinib than gefitinib. Whether the osimertinib is going to be better or not I think remains to be seen. I mean, those data, as I said, it’s not in direct comparator setting. |